Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.56 |
| ▸ | CTSK | P43235 | 4/20 | 0.56 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21457973 | 1.00 | CTSS (0.56) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL21457987 | 1.00 | CTSS (0.56) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL4389965 | 0.91 | CTSK (0.54) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL16463143 | 0.90 | ATM (0.58) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL16482788 | 0.90 | ATM (0.58) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL17097354 | 0.90 | ATM (0.58) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL4394791 | 0.89 | CTSK (0.52) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL28027548 | 0.89 | CTSK (0.52) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL20834865 | 0.88 | REN (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6342755 | 0.88 | KLK5 (0.56) | CTSSCTSKCTSBCTSLKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | OSAKA CITY UNIVERSITY (JP) | 2023-12-19 | — | — | US | disclosed |
| EP-3466421-B1 | COMPOSITION FOR THE TREATMENT OF PERIPHERAL NERVE DISORDERS | UNIV OSAKA CITY (JP) | 2022-11-30 | — | — | EP | disclosed |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | OSAKA CITY UNIVERSITY (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190270770-A1 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | LANDSTEINER GENMED S L | 2019-09-05 | — | — | US | disclosed |
| US-10294269-B2 | Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation | LANDSTEINER GENMED, S.L. (ES) | 2019-05-21 | — | — | US | disclosed |
| EP-3466421-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | Osaka City University (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-3191112-B1 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | LANDSTEINER GENMED S L (ES) | 2019-03-20 | — | — | EP | disclosed |
| EP-2647386-B1 | LISSENCEPHALY THERAPEUTIC AGENT | UNIV OSAKA CITY (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-9539298-B2 | Lissencephaly therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20160250276-A1 | LISSENCEPHALY THERAPEUTIC AGENT | OSAKA CITY UNIVERSITY (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371359-B2 | Lissencephaly therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2016-06-21 | — | — | US | disclosed |
| CN-103282043-B | Congenital agyria therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2015-09-30 | — | — | CN | disclosed |
| EP-2647386-A1 | LISSENCEPHALY THERAPEUTIC AGENT | Osaka City University (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130244945-A1 | LISSENCEPHALY THERAPEUTIC AGENT | OSAKA CITY UNIVERSITY | 2013-09-19 | — | — | US | disclosed |
| CN-103282043-A | Lissencephaly therapeutic agent | UNIV OSAKA CITY | 2013-09-04 | — | — | CN | disclosed |
| EP-1692098-B1 | ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF | SENJU PHARMA CO (JP) | 2009-10-28 | — | — | EP | disclosed |
| US-7491705-B2 | Alpha-ketoamide derivative, and production method and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20070004643-A1 | Alpha-ketoamide derivative, and production method and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244945-A1 | LISSENCEPHALY THERAPEUTIC AGENT | ASPH, DCX, ERH | CTSS 2276/4885CTSK 3603/4885CTSB 2800/4885 |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | PMP22, PRPH, NGF | CTSS 4112/4885CTSK 4322/4885CTSB 3143/4885 |
| US-10294269-B2 | Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation | DPP4, DPP3, DPP8 | CTSS 1014/4885CTSK 605/4885CTSB 565/4885 |
| US-20190270770-A1 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | DPP4, DPP3, DPP8 | CTSS 1014/4885CTSK 605/4885CTSB 565/4885 |
| US-20070004643-A1 | Alpha-ketoamide derivative, and production method and use thereof | CAPN1, CAPN2, CAPNS1 | CTSS 305/4885CTSK 251/4885CTSB 143/4885 |
| US-20160250276-A1 | LISSENCEPHALY THERAPEUTIC AGENT | ASPH, DCX, P4HA1 | CTSS 2361/4885CTSK 3608/4885CTSB 2893/4885 |
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | PMP22, PRPH, NGF | CTSS 4112/4885CTSK 4322/4885CTSB 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.